- Investing Ideas
- U.S. Pharmaceuticals & Biotech High ROE Growth Engines
U.S. Pharmaceuticals & Biotech High ROE Growth Engines
Results
15
15 companies
Incyte
Market Cap: US$24.0b
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
INCY
US$120.56
7D
0.9%
1Y
53.8%
Exelixis
Market Cap: US$14.3b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$52.20
7D
-6.7%
1Y
39.6%
ACADIA Pharmaceuticals
Market Cap: US$5.0b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$29.21
7D
12.9%
1Y
18.7%
CareDx
Market Cap: US$2.3b
Provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.
CDNA
US$46.69
7D
6.8%
1Y
290.1%
Innoviva
Market Cap: US$1.5b
Operates as a biopharmaceutical company in the United States and internationally.
INVA
US$21.11
7D
-0.5%
1Y
14.4%
Theravance Biopharma
Market Cap: US$878.0m
A biopharmaceutical company, develops and commercializes medicines in the United States.
TBPH
US$16.94
7D
0.5%
1Y
47.0%
Zevra Therapeutics
Market Cap: US$614.3m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$11.88
7D
23.2%
1Y
-2.1%
CorMedix
Market Cap: US$590.0m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$7.41
7D
3.1%
1Y
-38.0%
Q32 Bio
Market Cap: US$490.8m
A clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
QTTB
US$16.20
7D
4.1%
1Y
805.0%
Abeona Therapeutics
Market Cap: US$393.3m
A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
ABEO
US$6.90
7D
6.6%
1Y
10.0%
Elite Pharmaceuticals
Market Cap: US$388.7m
A specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals.
ELTP
US$0.36
7D
-4.0%
1Y
-36.7%
Compugen
Market Cap: US$216.0m
A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
CGEN
US$2.30
7D
-1.5%
1Y
59.7%
Oramed Pharmaceuticals
Market Cap: US$176.8m
Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
ORMP
US$4.30
7D
4.4%
1Y
106.7%
Vaxart
Market Cap: US$142.2m
A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform.
VXRT
US$0.57
7D
8.2%
1Y
45.9%
Spero Therapeutics
Market Cap: US$73.5m
A clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
SPRO
US$1.27
7D
8.5%
1Y
-42.0%